Latest Myopia News

VTI Appoints Dr. Juan Carlos Aragón as CEO and Executive Director

ATLANTA — Visioneering Technologies, Inc. (ASX: VTI), a medical device company and producer of the NaturalVue Multifocal 1 Day Contact Lenses, announced the appointment of Dr. Juan Carlos Aragón as Chief Executive Officer and Executive Director, effective October 1, 2023.

Dr. Aragón brings over 30 years of leadership in the vision care industry to VTI. His experience includes senior executive leadership positions in several large international vision care companies, managing divisions for the Americas, Asia Pacific, and Europe. Most recently, he was president of CooperVision Specialty EyeCare, which incorporates soft custom and rigid gas permeable contact lens product offerings, including orthokeratology, scleral lenses, and myopia management products for global markets, including China. In the previous 23 years, Dr. Aragón has held several senior positions within CooperVision and a predecessor company. He also held positions with Bausch + Lomb and CIBA Vision, a predecessor company to Alcon.

VTI’s Chairman, Dr. David J. Mazzo, PhD, said, on behalf of the board of directors, “We are delighted and extremely fortunate to have Dr. Aragón join the VTI team to help lead the company through the next phase of its growth. With his background leading global businesses, expertise working with myopia management, and extensive experience with the China vision care market, he is ideally suited to propel Visioneering to future success. JC, as he is known by many, is well recognized as a leader in the global vision care industry. We expect his reputation and extensive contacts will contribute greatly to creating new opportunities for VTI.”

Dr. Aragón further affirmed the potential commercial growth and opportunities at VTI: “I have known VTI since its initial commercialization in 2016. In my view, NaturalVue Multifocal is an extraordinary product for managing both myopia and presbyopia. I have been impressed by the success to date of the highly capable team at VTI and very much look forward to working with them to achieve VTI’s full potential in existing markets and new territories, especially in China. With the interim one-year results of the PROTECT Clinical Study to be released in the coming months, I feel fortunate to have the opportunity to take the helm at VTI at this pivotal time for the company.”

Dr. Aragón is a former board member and former Chair of the Global Myopia Awareness Coalition (GMAC), a diverse group of leading companies working together to protect children from the effects of myopia. His leadership in and service to GMAC highlights Dr. Aragón’s dedication to vision care and the respect the industry has for his capabilities. He also volunteers as Chairman of the Board of Optometry Giving Sight, and he has been a board member of the Brien Holden Foundation, the International Agency for the Prevention of Blindness, and Vision Aid Overseas (now Vision Action). He was also a Board Member of SightGlass Vision, now a Joint Venture of CooperVision and EssilorLuxottica.

To Top